Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study of Safety and Efficacy of Microporous, Fractionated, Protonated Zirconium Silicate in Mild to Moderate Hyperkalemia
Brief Summary: Acute Phase: It is hypothesized that ZS (zirconium silicate) is more effective than placebo control (alternative hypothesis) in lowering S-K levels in subjects with S-K between 5.0 - 6.5 mmol/l versus no difference between ZS and placebo control (null hypothesis).

Subacute Phase (randomized withdrawal): It is hypothesized that ZS once daily is more effective than placebo control (alternative hypotheses) in maintaining normokalemic levels (3.5 - 4.9 mmol/l) among subjects completing the Acute Phase versus no difference between each ZS dose and respective placebo controls (null hypotheses).


Options:
A: Arm Label: Zirconium silicate (acute phase); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (acute phase) | Arm Label: Placebo (acute phase); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (acute phase) | Arm Label: Zirconium silicate (subacute phase); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (subacute phase) | Arm Label: Placebo (subacute phase); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo ( subacute phase) | Intervention Type: DRUG; Name: Zirconium silicate (acute phase); Assigned to Arm(s): Zirconium silicate (acute phase) | Intervention Type: DRUG; Name: Zirconium silicate (subacute phase); Assigned to Arm(s): Zirconium silicate (subacute phase) | Intervention Type: DRUG; Name: Placebo (acute phase); Assigned to Arm(s): Placebo (acute phase) | Intervention Type: DRUG; Name: Placebo ( subacute phase); Assigned to Arm(s): Placebo (subacute phase)
B: Arm Label: Patiromer; Type: ACTIVE_COMPARATOR; Interventions: Drug: Patiromer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Patiromer; Assigned to Arm(s): Patiromer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sodium zirconium cyclosilicate 10 g three times daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Placebo once daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sodium zirconium cyclosilicate 5 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 10 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 15 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Intervention Type: DRUG; Name: Sodium zirconium cyclosilicate; Assigned to Arm(s): Sodium zirconium cyclosilicate 10 g once daily, Sodium zirconium cyclosilicate 10 g three times daily, Sodium zirconium cyclosilicate 15 g once daily, Sodium zirconium cyclosilicate 5 g once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo once daily
D: Arm Label: Stratum 1: 8.4 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 1: 16.8 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 1: 25.2 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 2: 16.8 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 2: 25.2 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 2: 33.6 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 1: 8.4 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 2: 16.8 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 1: 16.8 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 1: 25.2 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 2: 25.2 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 2: 33.6 g/d patiromer | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): Stratum 1: 16.8 g/d patiromer, Stratum 1: 25.2 g/d patiromer, Stratum 1: 8.4 g/d patiromer, Stratum 2: 16.8 g/d patiromer, Stratum 2: 25.2 g/d patiromer, Stratum 2: 33.6 g/d patiromer | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): Stratum 1: 16.8 g/d patiromer, Stratum 1: 25.2 g/d patiromer, Stratum 1: 8.4 g/d patiromer, Stratum 2: 16.8 g/d patiromer, Stratum 2: 25.2 g/d patiromer, Stratum 2: 33.6 g/d patiromer

Answer: A